Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer

Stopped early · Phase 2

Conditions studied: Carcinoma, Non-Small-Cell Lung

In brief

This study assigned subjects to either cisplatin/vinorelbine or cisplatin/pemetrexed chemotherapy using a genomic based expression profile to determine chemotherapy sensitivity in completely resected early stage non-squamous non-small-cell lung cancer (NSCLC). The vinorelbine-sensitive tumors group received Vinorelbine followed by cisplatin, while the pemetrexed-sensitive tumors group received pemetrexed followed by cisplatin. The primary objective of this trial was to determine whether genomic-based adjuvant chemotherapy treatment increased the 2-year progression-free survival rate in completely resected patients with NSCLC compared to historic controls. Secondary objectives included: 1) estimation of the percentage of completely resected NSCLC tumors that can be adequately analyzed and used to direct specific adjuvant chemotherapy; 2) estimation of the proportion of patients who are assigned to treatment with vinorelbine and pemetrexed; 3) evaluation of drug sensitivity patterns of cisplatin and pemetrexed in both treatment arms; 4) description of the overall median survival experience of treated patients; and 5) assessment of patient understanding and perceptions of participating in a clinical trial evaluating cancer genomics for adjuvant treatment of early stage lung cancer.

Key facts

Study ID: NCT00545948
Run by: Duke University
People needed: 31
Starts: 2007-12-01
Expected to finish: 2012-01-01
Last updated by the study team: 2014-07-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Patients are eligible to be included in the study only if they meet all of the following criteria:
Patients with completely resected stage IB (> 4 cm), II, or IIIA Non-Squamous NSCLC. Patient must be enrolled and begin therapy within 4 to 12 weeks from the date of complete surgical resection.
Fresh tissue must be available for genomics expression profiling.
ECOG performance status of 0 or 1.
NO prior chemotherapy, radiation therapy, or biologic/targeted therapy within the last 5 years. Prior therapy with low dose methotrexate or similar medications is allowed if therapy used to treat non-malignant conditions.
Age ≥ 18 years.
No previous or concomitant malignancy in the past 5 years other than curatively-treated carcinoma in situ of the cervix, or basal cell or squamous cell carcinoma of the skin.
No other serious medical or psychiatric illness.
Signed informed consent.
Required laboratory data within one week of enrollment:
ANC or AGC ≥ 1500 per uL;
Platelets ≥ 100,000 per uL;
Total bilirubin ≤ 1.5 mg/dL;
Creatinine ≤ 2 mg/dL; creatinine clearance ≥ 45 mL/min;
SGOT/SGPT ≤ 1.5x ULN.
Females of child-bearing potential (not surgically sterilized and between menarche and 1 year post menopause) must test negative for pregnancy within 7 days prior to or at the time of enrollment based on a serum pregnancy test. Both sexually active males and females of reproductive potential must agree to use a reliable method of birth control, as determined by the patient and their health care team, during the study and for 3 months following the last dose of study drug.

You may not qualify if…

Patients will be excluded from the study if they meet any of the following criteria:
Treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.
Concurrent administration of any other anti-tumor therapy (see #4 inclusion for exceptions).
Inability to comply with protocol or study procedures.
Active infection requiring IV antibiotics, antifungal or antiviral agents, that in the opinion of the investigator would compromise the patient's ability to tolerate therapy.
Major surgery (other than definitive lung cancer surgery) within two weeks of study or other serious concomitant systemic disorders that, in the opinion of the investigator, would compromise the safety of the patient or compromise the patient's ability to complete the study.
Myocardial infarction having occurred less than 6 months before inclusion, any known uncontrolled arrhythmia, symptomatic angina pectoris, active ischemia, or cardiac failure not controlled by medications.
Contraindication to corticosteroids.
Inability or unwillingness to take folic acid or vitamin B12 supplementation.
Unwillingness to stop taking herbal supplements while on study.
Presence of clinically significant third-space fluid collections (for example, ascites or pleural effusions) that cannot be controlled by drainage or other procedures prior to study entry and throughout study enrollment as the distribution of pemetrexed in this fluid space is not fully understood.
Inability to discontinue administration of aspirin at a dose > 1300 mg/day or other long acting, non-steroidal anti-inflammatory agents for 2 days before, the day of, and 2 days after the dose of pemetrexed (5 days prior for long-acting agents such as piroxicam). Moderate dose ibuprofen may be continued.
Female patients that are pregnant or breast-feeding.

Where it is running

Palm Beach Cancer Institute — West Palm Beach, Florida, United States
University of Chicago Medical Center — Chicago, Illinois, United States
Presbyterian HealthCare — Charlotte, North Carolina, United States
Duke University Medical Center — Durham, North Carolina, United States
Maria Parham Hospital — Henderson, North Carolina, United States
Scotland HealthCare System (Scotland Memorial Hospital) — Laurinburg, North Carolina, United States
Southeastern Regional Medical Center, Gibson Cancer Center — Lumberton, North Carolina, United States
Duke Raleigh Hospital — Raleigh, North Carolina, United States
Johnston Memorial Hospital Authority — Smithfield, North Carolina, United States
Columbus County Hospital — Whiteville, North Carolina, United States
Beaufort Memorial Hospital — Beaufort, South Carolina, United States
Coastal Cancer Center — Myrtle Beach, South Carolina, United States
Community Memorial Health Center — South Hill, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.